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Abstract
Continuing improvements in analytical technology along with an increased interest in performing comprehensive,
quantitative metabolic profiling, is leading to increased interest pressures within the metabolomics community to develop
centralized metabolite reference resources for certain clinically important biofluids, such as cerebrospinal fluid, urine and
blood. As part of an ongoing effort to systematically characterize the human metabolome through the Human Metabolome
Project, we have undertaken the task of characterizing the human serum metabolome. In doing so, we have combined
targeted and non-targeted NMR, GC-MS and LC-MS methods with computer-aided literature mining to identify and quantify
a comprehensive, if not absolutely complete, set of metabolites commonly detected and quantified (with today’s
technology) in the human serum metabolome. Our use of multiple metabolomics platforms and technologies allowed us to
substantially enhance the level of metabolome coverage while critically assessing the relative strengths and weaknesses of
these platforms or technologies. Tables containing the complete set of 4229 confirmed and highly probable human serum
compounds, their concentrations, related literature references and links to their known disease associations are freely
available at http://www.serummetabolome.ca.
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Introduction
Metabolomics is a branch of ‘‘omics’’ research primarily
concerned with the high-throughput identification and quantifi-
cation of small molecule (,1500 Da) metabolites in the metabo-
lome [1,2]. While in other ‘‘omics’’ fields, including genomics,
transcriptomics and proteomics thousands of targets are routinely
identified and quantified at a time, the same cannot be said of
most metabolomics efforts. Indeed, the majority of published
metabolomic studies identify and/or quantify fewer than two
dozen metabolites at a time [3]. In other words, metabolomics
currently lacks the quantitative horsepower that characterizes the
other ‘‘omics’’ sciences. This limitation has mostly arisen because
metabolomics has, until recently, lacked the electronic database
equivalent of GenBank or UniProt [2] for compound identifica-
tion. With the release of the Human Metabolome Database
(HMDB) [4,5] and other related compound or spectral resources
such as KEGG [6], LipidMaps [7], PubChem [8], ChEBI [9],
MMCD [10], Metlin [11] and MassBank [12], we believe the field
has taken an important step towards making metabolomics studies
much more quantitative and far more expansive in terms of
metabolite coverage. In an effort to further enhance the use of
quantitative metabolomics, we (and others) have started to
systematically determine the detectable metabolic composition of
clinically important biofluids and tissue types [13,14,15]. Follow-
ing our comprehensive characterization of the cerebrospinal fluid
metabolome [15] we continue herein with a comprehensive
characterization of the human serum metabolome.
Blood is composed of two parts: a cellular component consisting
of red and white blood cells and platelets, and a liquid carrier, called
plasma. Plasma is the straw-colored liquid in which blood cells are
suspended, which accounts for approximately 50–55% of blood
volume, with blood cells (erythrocytes, leukocytes and platelets)
accounting for the remaining portion [16]. Plasma is obtained from
a blood sample, if anti-coagulants are introduced, by simply
centrifuging the sample and removing or decanting the most
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blood is allowed to clot, the supernatant fluid is called the serum,
which is less viscous than plasma and lacks fibrinogen, prothrombin
and other clotting proteins [17]. Both plasma and serum are
aqueous solutions (about 95% water) containing a variety of
substances including proteins and peptides (such as albumins,
globulins, lipoproteins, enzymes and hormones), nutrients (such as
carbohydrates, lipids and amino acids), electrolytes, organic wastes
and variety of other small organic molecules suspended or dissolved
in them. In terms of small molecules, the compositions of plasma
and serum appear to be very similar (based on current analytical
techniques).Theprimarydifferenceappearstolieinthecompounds
involved in the clotting process; although modest discrepancies in
the relative distribution of some compounds between these pools
have also been reported [18] The clotting of blood maximally
stimulates blood cell eicosanoid biosynthesis, and thus serum levels
of these metabolites do not reflect physiological concentrations [19].
Therefore, due to their clinical importance, measures of plasma
eicosanoids have been included in this report. However, to improve
readability of the manuscript, the term ‘‘serum’’ is used when
referring to the liquid portion of blood, except where explicit
measures in plasma are discussed.
Blood serum is a primary carrier of small molecules in the body.
Not only does this biofluid play a critical role in transporting
dissolved gases, nutrients, hormones and metabolic wastes, but it
also plays a key role in the regulation of the pH and ion
composition of interstitial fluids, the restriction of fluid losses at
injury sites, the defense against toxins and pathogens and the
stabilization of body temperature [20]. Because blood bathes every
tissue and every organ in the body, it essentially serves as a liquid
highway for all the molecules that are being secreted, excreted or
discarded by different tissues in response to different physiological
needs or stresses. Of crucial clinical importance is the fact that
tissue lesions, organ dysfunctions and pathological states can alter
both the chemical and protein composition of blood plasma/
serum. As a result, most of today’s clinical tests are based on the
analysis of blood plasma or blood serum [21,22].
Being an important and easily accessible biological fluid, blood
has been the subject of detailed chemical analysis for more than 70
years [21,23]. Extensive tables of normal reference ranges have
been published for many blood gases, ions and about 100
metabolites [22,24,25,26,27]. In addition to these referential
clinical chemistry studies, several groups have applied various
‘‘global’’ metabolomic or metabolite profiling methods, such as
high resolution nuclear magnetic resonance (NMR) spectroscopy
[28,29], high performance liquid chromatography (HPLC) [30],
amino acid analysis [31,32] liquid chromatography – mass
spectrometry (LC-MS) [33,34], high performance liquid chroma-
tography – mass spectrometry/mass spectrometry (HPLC-MS/
MS) [35], gas chromatography – mass spectrometry (GC-MS)
[36,37], high resolution capillary GC-MS [38], GCxGC-MS [39],
ultrahigh performance liquid chromatography – mass spectrom-
etry (UPLC-MS) [40] and high resolution reversed-phase LC
(RPLC) with high resolution quadrupole time-of-flight mass
spectrometry (QqTOF) [41] to characterize the serum/plasma
metabolome with varying degrees of success. Perhaps the most
complete global characterization of the blood metabolome to date
was described by Lawton and colleagues [13]. Using a
combination of GC-MS and LC-MS, this group reported the
identification of more than 300 metabolites or metabolic features
(of which 79 were explicitly identified) in the human plasma
metabolome. A similar GC-TOF-MS study identified nearly 80
low molecular weight metabolites in blood plasma [42], whereas a
recent high resolution capillary GC-MS study has provided a very
extensive list of lipid fatty acids in blood [38]. In addition to these
global metabolomic studies, hundreds of other ‘‘targeted’’
metabolite studies have been conducted on blood plasma and
serum that have led to the identification and quantification of
hundreds of other serum metabolites. Unfortunately, this infor-
mation is not located in any central repository. Instead it is highly
dispersed across numerous journals and periodicals [4].
To facilitate future research into blood chemistry and blood
metabolomics, it is crucial to establish a comprehensive,
electronically accessible database of the detectable metabolites in
human blood, plasma and/or serum. This document presents just
such a database, describing the metabolites that can be detected in
human serum (along with signaling molecules in blood plasma),
along with their respective concentrations and disease associations.
This resource was assembled using a combination of both
experimental and literature-based research. Experimentally, we
used high-resolution NMR spectroscopy, GC-MS, TLC/GC-MS,
LC-MS, UPLC-MS/MS, and direct flow injection (DFI) MS/MS
methods to identify, quantify and validate more than 4000 plasma
and serum metabolites. To complement these ‘‘global’’ metabolic
profiling efforts, our team also surveyed and extracted metabolite
and disease-association data from more than 2000 books and
journal articles that had been identified through computer-aided
literature and in-house developed text-mining software. This
‘‘bibliomic’’ effort yielded data for another 665 metabolites. The
resulting Serum Metabolome Database (SMDB) (http://www.
serummetabolome.ca) is a comprehensive, web-accessible resource
containing these 4229 confirmed and probable serum/plasma
compounds, their corresponding concentrations and links to
disease associations that were revealed or identified from these
combined experimental and literature mining efforts.
In undertaking thisstudywe chose to emphasize breadth over depth.
In other words, rather than producing detailed, gender, ethnic or age-
specific ranges for hundreds or thousands of patients for a few
compounds, we instead produced a broad survey for hundreds or
thousands of compounds from a relatively modest number of
individuals. While some of the resulting (literature or experimentally
derived) concentration values for many of these compounds might not
be appropriate for routine clinical studies, they do provide a far more
complete and quantitative picture of the plasma/serum metabolome
than has previously been achieved. They also provide ‘‘ballpark’’
concentration values for many metabolites that have never been
measured or whose concentration values are not widely known.
Overall, the intent of this study was to help both the metabolomics and
blood research communities address four key questions: 1) What
compounds can be or have ever been identified in blood? 2) What are
the approximate concentration ranges for these metabolites? 3) What
portion of the serum metabolome can be routinely identified and/or
quantified using untargeted or ‘‘global’’ metabolomics methods? and 4)
What analytical methods (NMR, GC-MS, LC-MS, DFI-MS/MS,
etc.) are best suited for comprehensively characterizing the serum
metabolome? We believe that answers to these questions provide a
more suitable baseline for both future and ongoing blood metabolomic
studies (e.g. the HUSERMET study [43] (http://www.husermet.org/).
Indeed, such a baseline would allow more prudent selection of
appropriate metabolomics platforms and eventually lead to a more
complete accounting of age, gender, diet and ethnicity variations.
Results and Discussion
The Content of the Human Serum Metabolome – The
Serum Metabolome Database
A complete listing of the identity and quantity of endo-
genous metabolites that can be detected in human serum is
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www.serummetabolome.ca). This freely available, easily queried,
web-enabled database provides a list of the metabolite names, level
of verification (confirmed or probable), normal and disease-
associated concentration ranges, diseases and references for all (to
the best of our knowledge) human serum metabolites that have
ever been detected and quantified in the literature. It also contains
the concentration data compiled from the experimental studies
described here. Each serum metabolite entry in this database is
linked to a MetaboCard button that, when clicked, brings up
detailed information about that particular entry. This detailed
information includes nomenclature, chemical, clinical and molec-
ular/biochemical data. Each MetaboCard entry contains more
than 110 data fields many of which are hyperlinked to other
databases (KEGG, PubChem, MetaCyc, ChEBI, PDB, Swiss-
Prot, and GenBank) as well as to GeneCard IDs, GeneAtlas IDs
and HGNC IDs for each of the corresponding enzymes or proteins
known to act on that metabolite. Additionally, SMDB through its
MetaboCard/HMDB links includes nearly 300 hand-drawn,
zoomable and fully hyperlinked human metabolic pathway maps.
These maps are intended to help users visualize the chemical
structures on metabolic maps and to get detailed information
about metabolic processes. These SMDB pathway maps are quite
specific to human metabolism and explicitly show the subcellular
compartments where specific reactions are known to take place.
SMDB’s simple text query (TextQuery) supports general text
queries including names, synonyms, conditions and disorders.
Clicking on the Browse button (on the SMDB navigation panel)
generates a tabular view that allows users to casually scroll through
the database or re-sort its contents by compound name or by
concentration. Users can choose either the ‘‘Metabolite View’’ or
‘‘Associated Condition View’’ to facilitate their browsing or
searching. Clicking on a given MetaboCard button brings up
the full data content (from the HMDB) for the corresponding
metabolite. The ChemQuery button allows users to draw or write
(using a SMILES string) a chemical compound to search the
SMDB for chemicals similar or identical to the query compound.
ChemQuery also supports chemical formula and molecular weight
searches. The TextQuery button supports a more sophisticated
text search (partial word matches, misspellings, etc.) of the text
portion of SMDB. The SeqSearch button allows users to conduct
BLAST sequence searches of the 6252 protein sequences
contained in SMDB. Both single and multiple sequence BLAST
queries are supported. The DataExtractor button opens an easy-
to-use relational query search tool that allows users to select or
search over various combinations of subfields. The DataExtractor
is the most sophisticated search tool in SMDB. SMDB’s MS
Search allows users to submit mass spectral files (MoverZ format)
that will be searched against the Human Metabolome database
(HMDB)’s library of MS/MS spectra. This potentially allows facile
identification of serum metabolites from mixtures via MS/MS
spectroscopy. SMDB’s NMR Search allows users to submit peak
lists from
1Ho r
13C NMR spectra (both pure and mixtures) and to
have these peak lists compared to the NMR libraries contained in
the HMDB. This allows the identification of metabolites from
mixtures via NMR spectroscopy. The Download button provides
links to collected sequence, image and text files associated with the
SMDB. The Explain button lists source data used to assemble the
SMDB.
Currently the SMDB contains information on 4229 detectable
metabolites (both confirmed and probable) and 9225 concentra-
tion ranges or values associated with different conditions and
disorders. This is not a number that will remain unchanged.
Rather it reflects the total number of metabolites – most of which
are endogenous - that have ever been detected and quantified by
others and ourselves. Certainly as technology improves, we
anticipate this number will increase as other, lower abundance,
metabolites, are detected and added to future versions of the
SMDB. Likewise, if the list was expanded to include intermittent,
exogenous compounds such as all possible drugs or drug
metabolites or rare food additives and food-derived phytochem-
icals, the database could be substantially larger.
Inspection of the on-line tables in SMDB generally shows that
human serum contains a substantial number of hydrophobic or
lipid-like molecules. This is further emphasized in Table 2, which
provides a listing of the metabolite categories in human serum and
the number of representative compounds that can be found in this
biofluid. Overall, the composition of human serum is dominated
by diglycerides, triglycerides, phospholipids, fatty acids, steroids
and steroid derivatives. This simply reinforces the fact that serum
(i.e. blood) is a key carrier of lipoproteins, fats and hydrophobic
nutrients. Other small molecule nutrients found in high abun-
dance in serum include amino acids (10 mM–1155 mM), glucose,
glycerol, lactate, oxygen, carbon dioxide (in the form of
bicarbonate ions) and several waste or catabolic byproducts such
as urea and creatinine. A more detailed description of our findings
is given in the following 6 sections covering: 1) Literature Review/
Text Mining; 2) NMR; 3) GC-MS; 4) LC-ESI-MS/MS Targeted
Lipid Profiling; 5) Lipidomics via TLC/GC-FID; and 6) DFI MS/
MS.
Metabolite Concentration in Serum – Literature Survey
In addition to the experimentally derived values obtained for
this study, the serum metabolome database (SMDB) also presents
literature-derived concentrations of the metabolites with references
to either PubMed IDs or to clinical texts. In many cases, multiple
concentration values are given for ‘‘normal’’ conditions. This is
done to provide users/readers with a better estimate of the
potential concentration variations that different technologies or
laboratories may measure. As a general rule, there is good
agreement between most laboratories and methods. However, the
literature results presented in the SMDB do not reflect the true
state of the raw literature. A number of literature-derived
concentration values were eliminated through the curation process
after being deemed mistaken, disproven (by subsequent published
studies), mis-typed or physiologically impossible. Much of the
curation process involved having multiple curators carefully
reading and re-reading the primary literature to check for unit
type, unit conversion and typographical inconsistencies.
Other than the inorganic ions and gases such as sodium
(144 mM), chlorine (110 mM), bicarbonate/carbon dioxide
(25 mM), iron (9 mM), oxygen (6 mM), potassium (4.5 mM),
calcium (2.5 mM), phosphorus/phosphate and sulfur/sulfide
(,1 mM) and magnesium (800 mM), the 12 most abundant
organic metabolites found in serum are D-glucose (5 mM), total
cholesterol (5 mM), melanin (5 mM), urea (4 mM), ATP (3 mM),
glyceraldehyde (1.5 mM), cholesterol esters (0.4–1.5 mM), L-lactic
acid and fructosamine (,1 mM), L-glutamine (500 mM), L-
alanine (500 mM), methanol (460 mM), glycine, L-lysine, uric acid
(350 mM), and (R)-3-hydroxybutyric acid (350 mM). The least
abundant (detectable) metabolites in serum include several
diacylglycerols (DGs), (.1 pM), LPS-o-antigen (2pM), vitamin
K1 2,3-epoxide (2 pM), 13,14-dihydro prostaglandin E1 (PGE1)
(3 pM), substance P and prostaglandin E1 (4 pM), various
glycerophospholipids (4–100 pM), vasopressin (5 pM), 11-trans-
Leukotriene C4 (10 pM), nitric oxide (12 pM), LPS core (14 pM),
thyroxine (15 pM), 3,5-diiodothyronine (16 pM), epietiocholano-
lone, thromboxane B3 and cotinine N-oxide (17 pM), thyroxine
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the current lower limit of detection for metabolites in serum is in
the low picomolar range and that the concentration range of
analytes in serum spans nearly 11 orders of magnitude. As might
be expected, many of the least abundant compounds are
hormones or signaling molecules while the most abundant
molecules serve as buffering agents or stabilizing salts.
One point that is particularly interesting is the fact that the
concentration of the average metabolite in normal serum varies by
about +/250%, with some metabolites varying by as much as +/
2100% (such as D-glucose, L-lactic acid, L-glutamine, glycine).
Therefore, drawing conclusions about potential disease biomark-
ers without properly taking into account this variation would be ill-
advised. We believe that these relatively large ranges of metabolite
concentrations are due to a number of factors, including age,
gender, genetic background, diurnal variation, health status,
activity level, and diet. Indeed, some SMDB entries explicitly
show such variations based on the populations (age, gender) from
which these metabolite concentrations were derived. Clearly more
study on the contributions to the observed variations in serum is
warranted, although with thousands of metabolites to measure for
dozens of conditions, these studies will obviously require significant
technical and human resources.
Experimental Quantification and Identification – NMR
The NMR spectrum of ultrafiltered serum is remarkably simple
and surprisingly uncomplicated (Figure 1) This made the identifi-
cation and quantification of serum metabolites relatively easy.
Typically 98% of all visible peaks were assigned to a compound and
more than 95% of the spectral area could be routinely fitted using
the Chenomxspectral analysis software. As seen in Figure 1, most of
the visible peaks can be annotated with a compound name. From
the 21 healthy control serum samples and the 54 serum samples
from the patient cohort, 20 and 53 were analyzed, respectively. A
total of 44 unique compounds were identified with an average of
3362 compounds being identified per sample. Twenty-five
compoundswereidentifiedineverysample,withthe most abundant
compounds being urea (6 mM), D-glucose (5 mM), L-lactic acid,
(1.4 mM), L-glutamine (0.51 mM) and glycerol (0.43 mM). The
least abundant compounds were carnitine (46 mM), acetic acid
(42 mM), creatine (37 mM), L-cysteine (34 mM), propylene glycol
(22 mM)andL-aspartic acid (21 mM).Thelowestconcentrationthat
could be reliably detected using NMR was 12.3 mM (for malonic
acid) and 14.5 mM (for choline). The complete list of average
compound concentrations and the frequency of their occurrence is
shown in Table 3. Significant efforts were made to identify the
‘‘rarer’’ or less frequently occurring compounds in a larger fraction
of serum samples. To this end, we collected NMR spectra for longer
periods of time and/or at higher field strengths. While this did
improvequantification accuracy, it did not lead to an increase in the
number of compounds detected. Inspection of Table 3 also reveals
the generally good agreement between the NMR-measured
concentrations and those reported in the literature (often obtained
by other analytical means).
Table 1. Summary of sample collection and analysis methods.
Number of
Samples Sample Source Number of samples analyzed by different methods
NMR
Untargeted
GC-MS
Targeted
GC-MS (oxylipins,
endo-
cannabionids)
Targeted
(DFI) MS/MS
UPLC-MS/MS
(oxylipins,
endocannabi-
onids)
Quantitative
Lipidomics
(TLC-methyl-
esterfication-
GC-MS)
Analysis
Location
75 (54
Patients,
21 Controls
James Hogg
iCAPTURE Centre
for Cardiovascular
and Pulmonary
Research and the
NCE CECR Centre
of Excellence for
Prevention of
Organ Failure
(PROOF Centre),
Vancouever BC,
Canada
75 7 controls - 21 controls - - Edmonton AB,
Canada
3 Clinical Laboratory
Medicine,
University of
Alberta,
Edmonton AB,
Canada
- - - - - 3 West Sacramento
CA, USA;
Edmonton AB,
Canada
70 Pennington Biomedical
Research
Center, Baton
Rouge LA, USA
- - 70 - 70 - Davis CA, USA
1 Clinical
Laboratory
Medicine,
University
of Alberta,
Edmonton AB, Canada
- - - 1 (three technical
replicates for
oxylipin analysis)
- Davis CA, USA
doi:10.1371/journal.pone.0016957.t001
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agree with the literature derived values. Forty-three out of the 44
compounds identified in the healthy control group, had concen-
tration values previously reported in the literature. We found that
35 compounds exhibited good agreement with literature values –
i.e., meaning the average NMR values fell within one standard
deviation of the literature value. In addition, seven compounds
had concentrations somewhat higher than previously reported
values (L-asparagine, glycerol, glycine, L-histidine, hypoxanthine,
methanol and propylene glycol), while two compounds had
concentrations lower than previously reported (L-cystine and
formic acid). Compounds exhibiting the greatest discrepancy
between NMR measured values and literature derived values
include: glycerol, hypoxanthine and propylene glycol. Propylene
glycol is likely an exogenous ‘‘contaminant’’ as it is widely used as
a solvent in many pharmaceuticals and as a moisturizer in
cosmetics, lotions, hand sanitizers, foods and toothpastes. Never-
theless, its ubiquity in so many consumer products has made it a
routinely observed component of human serum. Some of the
concentration discrepancies for the other compounds may be
explained by their inherent volatility or chemical instability
(hypoxanthine, methanol, formic acid). Other discrepancies may
be due to sample collection/preservation effects (the ultrafiltration
devices we used contain trace amounts of glycerol) or possibly
sample size effects (2 patients versus 35 patients). A third source of
variation may be technical problems with the separation or
extraction methods being used to obtain ‘‘clean’’ serum by
different laboratories. Blood is an inherently complex, multi-
component mixture and organic solvent extractions and ultrafil-
tration methods have different weaknesses. In particular, while
solvent extraction will only isolate soluble components, ultrafiltra-
tion will only isolate compounds not tightly associated with
macromolecules.
In contrast to the healthy controls, the NMR spectra of the
serum isolated from heart transplant patients tended to be slightly
more complex and somewhat more variable. A total of 44
compounds were identified from these samples with an average of
3262 compounds being identified per sample. Twenty-one
compounds were identified in every sample. The same level of
spectral coverage (98% peak identification, 95% spectral area) was
achieved with serum from the heart transplant samples as with the
healthy controls. While the rank order of the most abundant and
least abundant compounds was slightly different, the same
compounds appeared in both the ‘‘diseased’’ and ‘‘healthy’’ lists.
The complete list of average compound concentrations for the
heart transplant patients along with their frequency of occurrence
is shown in Table 3. Inspection of Table 3 again shows the
generally good agreement between the NMR-measured concen-
trations and those reported in the literature, although there are
clear and statistically significant differences between the average
values for the transplant patients and the normal or literature
derived values. Using a Student’s t-test we found that 22
Table 2. Chemical classes in the Serum Metabolome Database.
Compound class Number Compound class Number
Acyl glycines 10 Indoles and indole derivatives 12
Acyl phosphates 10 Inorganic ions and gases 20
Alcohol phosphates 2 Keto acids 8
Alcohols and polyols 40 Ketones 6
Aldehydes 3 Leukotrienes 8
Alkanes and alkenes 10 Lipoamides and derivatives 0
Amino acid phosphates 1 Minerals and elements 40
Amino acids 114 Miscellaneous 77
Amino alcohols 14 Nucleosides 24
Amino ketones 14 Nucleotides 24
Aromatic acids 22 Peptides 21
Bile acids 19 Phospholipids 2177
Biotin and derivatives 2 Polyamines 11
Carbohydrates 35 Polyphenols 22
Carnitines 22 Porphyrins 6
Catecholamines and derivatives 21 Prostanoids 23
Cobalamin derivatives 4 Pterins 14
Coenzyme A derivatives 1 Purines and purine derivatives 11
Cyclic amines 9 Pyridoxals and derivatives 7
Dicarboxylic acids 17 Pyrimidines and pyrimidine derivatives 2
Fatty acids 65 Quinones and derivatives 3
Glucuronides 8 Retinoids 11
Glycerolipids 1070 Sphingolipids 3
Glycolipids 15 Steroids and steroid derivatives 109
Hydroxy acids 129 Sugar phosphates 9
Tricarboxylic acids 2
doi:10.1371/journal.pone.0016957.t002
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two groups (using a cut-off P-value of 0.05; with no Bonferroni
correction). The most strongly differentiating compounds were D-
glucose, creatinine, L-valine, propylene glycol, citric acid, formic
acid and L-alanine (data not shown).
Serum from heart transplant patients also provided an
opportunity to look at the longitudinal or temporal metabolite
variation in individuals. Table S1 summarizes the mean
concentration and standard deviation seen over the 12-week
sampling period for the 44 metabolites as measured for all 9
transplant patients. Interestingly, the cross-sectional variation
appears, in general, to be larger than the longitudinal variation.
In other words, time-dependent metabolite changes within a single
individual tend to be smaller than the differences seen between
different individuals. Furthermore, in a recent analysis of the adult
human plasma metabolome, it was found that the concentrations
of about 30 metabolites can vary more than 50% between healthy
individuals due to age, gender and body mass index [13]. These
temporal variations may be somewhat exaggerated over what
might be seen in the general population given the surgical trauma
and medication that these heart transplant patients have
experienced over the sampling period. Nevertheless, the objective
of this study was to gain a better idea of the variability of serum
metabolite concentrations that can be found in living adults
(without an obvious metabolic disorder).
Combining the complete set of results from the healthy control
subjects with the results from the heart transplant patients, we
were able to identify and quantify a total of 49 different
compounds in serum using NMR spectroscopy (Table 3). We
would argue that this list of 49 metabolites along with the
concentrations listed in this table defines the ‘‘normal NMR-
detectable serum metabolome’’. Furthermore, we believe that now
that this set of 49 metabolites is known, it should allow the NMR
characterization of unprocessed serum to become routine, if not
highly automated.
GC-MS Identification and Quantification
Figure 2 illustrates a typical high resolution GC-MS total ion
chromatogram of the polar extracts from a serum sample of a
healthy adult subject. As can be seen in this figure, many of the
visible peaks can be annotated with a compound name, however
,40% of these peaks remain unidentified. This relatively low level
of coverage is a common problem in global or untargeted GC-MS
metabolomics studies. While some of these peaks may be due to
derivatization by-products or degraded metabolites, the lack of a
comprehensive GC-MS library for human metabolites (the NIST
mass spectra library contains only a small portion of metabolically
relevant compounds), also limits the attainable coverage from
automated library search algorithms. The use of other commer-
cially available reference libraries for GC-MS (i.e. the Fiehn GC-
MS library from Agilent) might have provided a slightly more
complete coverage of the serum metabolites, and the routine
application of more comprehensive libraries will likely expand the
list of commonly identified metabolites in the future.
All peaks corresponding to an identified metabolite were
verified with pure standards and correlated to literature values.
In total we identified 62 polar metabolites and 12 nonpolar
metabolites via GC-MS (Table 4). For full identification, the mass
spectra of the identified compounds not only had to match the EI-
MS spectra in the NIST database (with a match factor of .60%
and a probability score .20%), but also the retention index (RI) of
the compounds in the University of Alberta RI library, which
consists of 312 TMS-derivatized human metabolites. The targeted
GC-MS analysis for non-esterified fatty acids in the plasma
collected at the Pennington Biomedical Research Center (PBRC)
resulted in the identification and quantification of 25 compounds
(Table 5) in all samples. Trace levels of other fatty acids were
observed, but these were observed intermittently and the signal-to-
noise ratio was low enough that these compounds were not
deemed of sufficient quality to report. Of the detectable
compounds, 9 fatty acids were identified by both targeted and
global GC/MS analysis, while 2 were unique for the global
analysis (capric acid and arachidic acid) and 16 were unique for
the targeted approach. Notably, capric acid (C10:0) was
compromised by interference in the PBRC samples, while
arachidic acid (C20:0) was observed at ,0.05% of the total fatty
acid profile in ,60% of the subjects. Collectively, if both global
and targeted GC-MS analyses are taken into account, the number
of identified compounds is 90. Of the 74 polar metabolites
identified in the global GC-MS approach, only 33 could be clearly
quantified. This included 14 additional metabolites that were not
detected/quantified by NMR but that could be quantified by GC-
Figure 1. Typical 500 MHz
1H-NMR spectrum of healthy human serum. Numbers indicate the following metabolites: 1, imidazole; 2, urea; 3,
D-glucose; 4, L-lactic acid; 5, glycerol; 6, L-glutamine; 7, L-alanine; 8, DSS; 9, glycine; 10, L-glutamic acid; 11, L-valine; 12, L-proline; 13, L-lysine; 14, L-
histidine; 15, L-threonine; 16, propylene glycol; 17, L-leucine; 18, L-tyrosine; 19, L-phenylalanine; 20, methanol; 21,creatinine; 22, 3-hydroxybutyric
acid; 23, ornithine; 24, L-isoleucine; 25, citric acid; 26, acetic acid; 27, carnitine; 28, 2-hydroxybutyric acid; 29, creatine; 30, betaine; 31, formic acid; 32,
isopropyl alcohol; 33, pyruvic acid; 34, choline; 35, acetone; 36, glycerol.
doi:10.1371/journal.pone.0016957.g001
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Compound Name Healthy Subject Heart Transplant Literature Value
mM; (% Occurrence) mM; (% Occurrence) mM; (Range)
2-Hydroxybutyric acid 31.367.8; (73%) 24.3614.5; (92%) 54; (8–80)
Alpha-ketoisovaleric acid ND 10.765.5; (40%) NA
3-Hydroxybutyric acid 76.9666.3; (80%) 35.1633.9; (96%) 60.0620.0
Acetaminophen ND 33.5622.3; (8%) NA
Acetic acid 41.9615.1; (100%) 42.2617.3; (100%) 30; (22–40)
Acetoacetic acid 40.6636.5; (33%) 27.3614.4; (25%) 21.0; (0.0–86.0)
Acetone 54.4629.6; (86%) 13.265.5; (4%) 106; (35–170)
L-Alanine 427.2684.4; (100%) 3406126.2; (100%) 333; (259–407)
L-Arginine 113.6614.6; (100%) ND 111.6; (82.2–140.9)
L-Asparagine 82.467.3; (100%) 54.1621.7; (42%) 41610
L-Aspartic acid 20.966.1; (100%) ND 21.0+/25.0
Betaine 72622.4; (100%) 42.1619.3; (100%) 82; (20–144)
L-Carnitine 45.7611.6; (100%) 41.7623.9; (100%) 43; (26–79)
Choline 14.565.3; (90%) 9.764.5; (92%) 10.661.9
Citric acid 114.2627; (100%) 80.2644.9; (100%) 190; (30–400)
Creatine 36.7628.3; (100%) 33.8637.7; (100%) 54.8621.0
Creatinine 86.6618.8; (100%) 86.9644.5; (100%) 74.1610.9
L-Cysteine 33.5610.3; (100%) ND 52.0; (41.0–63.0)
L-Cystine 62.9627.8; (100%) ND 109.0624.0
Ethanol ND 40.2612.1; (13%) NA
Formic acid 32.8613.3; (48%) 19.866.8; (60%) 121.7697.8
D-Glucose 4971.36372.8; (100%) 374361272.9; (100%) 5400; (4700–6100)
L-Glutamic acid 97.4613.2; (100%) 72636.9; (40%) 21.0–150.0
L-Glutamine 510.46118.2; (100%) 376.86114.3; (100%) 586; (502–670)
Glycerol 431.66100.4; (100%) 133.9687.8; (100%) 82; (27–137)
Glycine 325.46126.8; (100%) 234.96181.1; (100%) 230; (178–282)
L-Histidine 131.2637.3; (100%) 46.1617.5; (100%) 82; (72–92)
Hypoxanthine 34.2610.3; (24%) 52.36*; (2%) 8.1; (5.3–11.0)
Isobutyric acid ND 8.461.9; (11%) NA
L-Isoleucine 60.7618.6; (100%) 44.6621.5; (100%) 62; (48–76)
Isopropyl alcohol 83.36132.8; (48%) 16.5622.5; (45%) Not available
L-Lactic acid 1489.46371.2; (100%) 1401.26692.1; (100%) 1510; (740–2400)
L-Leucine 98.7611.5; (100%) 74.8634.3; (100%) 123; (98–148)
L-Lysine 178.6658.2; (100%) 128.2655.3; (100%) 183.0634.0
Malonic acid 13.561.2; (14%) 105.7695.8; (9%) 15.060.6
Methanol 77.4616.3; (100%) 81.5655.2; (94%) 47.2610.3
L-Methionine 29.866.3; (33%) 17.369.5; (66%) 30; (22–38)
Methylmalonic acid ND 11.26*; (2%) NA
L-Ornithine 66.9615.3; (100%) 65.4630.4; (100%) 55; (39–71)
L-Phenylalanine 78.1620.5; (100%) 44.8621; (94%) 65.069.0
L-Proline 198.3664.8; (100%) 159.9686.3; (100%) 239.0670.0
Propylene glycol 22.363.3; (100%) 36.3619.9; (62%) 2; (0–5)
Pyruvic acid 34.5625.2; (81%) 50.2640; (87%) 64; (22–258)
L-Serine 159.8626.6; (100%) ND 137.0635.0
L-Threonine 127.7641; (100%) 83.4647.8; (96%) 140; (107–173)
L-Tryptophan 54.569.7; (100%) ND 48.7611.6
L-Tyrosine 54.569.7; (100%) 57.2624.4; (100%) 100; (55–147)
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compounds, oxalic acid and uric acid were found to have
concentrations greater than 1 standard deviation above previously
reported values. Comparisons between the NMR and GC-MS
measured concentrations (across the 26 compounds that were
quantified by both techniques) show generally good agreement
(within 20–50% of each other). GC-MS methods typically gave
higher concentrations of L-glutamic acid, L-isoleucine, L-methi-
onine and citric acid, and lower concentrations of L-alanine, L-
glutamine, glycine, L-serine, glucose and glycerol, compared to the
corresponding NMR results (data not shown). Compound
concentrations below 1 mM were associated with low signal-to-
noise ratio responses, limiting accurate quantification. However
these compounds were identified based on previously described
methods [69].
For GC-MS, the lowest limit of quantification was 8.3 mM for
alpha-hydroxyisobutyric acid. Given that there are slightly over
260 compounds in the serum-metabolome database (SMDB) with
normal concentrations .1 mM, one might have expected that the
GC-MS detectable compounds would have been much higher
than 90. The use of a relatively slow scanning quadrupole
instrument may partially explain the limited number of identifiable
peaks. This hardware can yield insufficient sampling across co-
eluting GC peaks, limiting complex spectral deconvolution.
However, comparisons to other reports on serum analysis by
GC-MS instruments suggest that this number is not unreasonable.
Indeed, a GC-MS (TOF) study on human plasma performed by
Jiye et al. yielded a list of 80 metabolites [42]. Our results, using a
less-sensitive GC-quadrupole-MS instrument, yielded 90 metabo-
lites (of which 57 were common to both studies). This is primarily
because we employed both polar and non-polar extraction
techniques to effectively increase the concentration of certain
metabolites. No doubt the use of better instruments (i.e. faster
scanning quadrupoles or TOF instruments with greater sensitiv-
ity), multiple extraction steps or the use of different derivatization
steps could have improved compound coverage. Indeed, in a
recently published study of the adult serum metabolome, the use of
fast-scanning quadrupole GC-MS resulted in the detection (but
not the quantification) of about 120 compounds [13]. It is also
notable that the authors of this study used a series of four solvent
Compound Name Healthy Subject Heart Transplant Literature Value
mM; (% Occurrence) mM; (% Occurrence) mM; (Range)
Urea 6074.662154.2; (100%) 3309.961844; (100%) 6500; (4000–9000)
L-Valine 212.3661.3; (100%) 144.2661.4; (100%) 233; (190–276)
Xanthine ND 51.26*; (2%) NA
*- only observed in one sample.
doi:10.1371/journal.pone.0016957.t003
Table 3. Cont.
Figure 2. Typical total ion chromatogram of serum from a healthy subject. Numbers indicate the following metabolites: 1, L-lactic acid; 2, L-
alanine; 3, oxalic acid; 4, L-valine; 5, urea; 6, L- L- L-leucine; 7, glycerol; 8, phosphoric acid; 9, L-isoleucine; 10, L-proline; 11, glycine; 12, L- L- L-serine; 13,
L-threonine; 14, L-methionine/L-aspartic acid; 15, aminomalonic acid; 16, pyroglutamic acid/L-glutamine; 17, L-glutamic acid; 18, L-phenylalanine; 19,
L-ornithine; 20, citric acid; 21,d-erythrofuranose; 22, D-fructose; 23, D-glucose; 24, D-galactose; 25, L-histidine; 26, L-lysine; 27, L-tyrosine; 28, gulonic
acid/mannonic acid; 29, D-glucopyranose; 30, 6-deoxy mannose; 31, palmitelaidic acid; 32, palmitic acid; 33, myo-inositol; 34, uric acid; 35, L-
tryptophan; 36, linoleic acid; 37, oleic acid; 38, stearic acid.
doi:10.1371/journal.pone.0016957.g002
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used in our study. These differences in metabolite numbers may
also reflect intrinsic differences in the GC–MS deconvolution
software and protocols.
Unlike NMR, where no chemical reactions or extractions are
required, GC-MS techniques can lead to the detection of
artifactual metabolites. For instance, one of the 76 metabolites
reported by Jiye et al. [42] was butylamine. In our study,
butylamine was also detected. However it was seen in both human
serum and in control (blank) samples. This strongly suggests that
butylamine is more an artifact of chemical derivatization, and not
a serum metabolite as originally reported. As we previously noted,
approximately 40% of the peaks remain unidentified in our GC–
MS analyses. These unidentified peaks in the total ion chromato-
gram were generally of low intensity, making spectral identifica-
tion difficult. Nevertheless, several standards were run to confirm
retention times and mass spectral information, likewise, other GC–
MS metabolome libraries were also queried to identify these
‘unknown’’ peaks, but without success.
It is also of some interest to compare the results of our GC-MS
studies with our NMR studies. As seen in Table 3 (NMR results),
Table 4–Table 6 (GC-MS results), and Figure 3, NMR and GC-
MS methods identify a common set of 29 compounds. Interest-
ingly, NMR detects 20 compounds that GC-MS methods cannot
detect while GC-MS detects 45 compounds that NMR cannot
routinely detect, including 3 very high abundance compounds
(phosphoric acid/phosphate, uric acid and N-acetyl-glycine).
There are many possible reasons for these differences in
instrumental detection. A compound might be found by NMR,
but not by GC-MS, if it is too volatile/nonvolatile for GC-MS
detection, lost in sample preparation or eluted during the solvent
delay. A compound might be found by GC-MS, but not by NMR,
if its protons are not detectable by NMR (uric acid, phosphate), or
if its concentration is below detectable limits (maltose, ribitol). In
all cases, the existence of NMR detectable metabolites was
explicitly checked in our GC-MS analyses and vice versa.
Together, NMR with targeted and global GC-MS identified and
quantified 135 mostly polar metabolites. Overall, GC-MS and
NMR appear to be complementary techniques for the identifica-
tion and quantification of small molecules in human serum.
UPLC-ESI-MS/MS (Targeted Lipid Profiling) Identification
and Quantification
While untargeted or global NMR and scanning MS techniques
are particularly useful for the identification and quantification of
polar metabolites of moderate abundance, they are not well suited
for low-abundance metabolites. On the other hand, LC-MS
methods are superb at the targeted identification of low-
abundance metabolites over a wide polarity range. To exploit
and explore these strengths in LC-MS, we chose to study an array
of metabolic products of polyunsaturated fatty acids found in the
liquid portion of the blood. In particular, we targeted (identified
and quantified) a subset of oxylipins (n=76), acyl-glycines (n=2),
acyl-ethanolamides (n=12), and mono-acylglycerols (n=6).
Oxylipins constitute a broad structural class of oxidized lipid
molecules, occurring in the low nM to mM concentrations that
perform a variety of functions when found in appropriate contexts
[52]. Acyl-amides and mono-acyl glycerols are also common
Table 4. List of 74 metabolites identified in human serum polar and lipid extracts.
Amino acids Organic acids Lipids Misc
Glycine 2-aminobutyric acid Arachidonic acid D-Fructose
L-Alanine Alpha-Hydroxyisobutyric acid Cholesterol D-Galactopyranose
L-Asparagine 2-Methylbutanoic acid Capric acid D-Galactose
L-Aspartic acid 3-Hydroxybutyric acid Dodecanoic acid Glucitol
L-Cysteine 4-Hydroxybutyric acid Arachidic acid D-Glucose
L-Cystine Aminomalonic acid Heptadecanoic acid Glycerol
L-Glutamic acid Benzoic acid Linoleic acid D-Glucopyranose
L-Glutamine Citric acid Oleic acid Hydroxyproline
L-Histidine Erythronic acid Palmitelaidic acid D-Maltose
L-Isoleucine Fumaric acid Palmitic acid Myo-inositol
L-Leucine Gluconic acid Stearic acid Acetylglycine
L-Lysine Glyceric acid Myristic acid N-Acetyl-L-Lysine
L-Methionine Isobutyric acid Acetaminophen
L-Ornithine Tartaric acid Phosphoric acid
L-Phenylalanine L-Lactic acid Ribitol
L-Proline Malonic acid Salicylic acid
L-Serine Methylmaleic acid Urea
L-Threonine Methylmalonic acid D-Xylitol
L-Tryptophan Nicotinic acid
L-Tyrosine Oxalic acid
L-Valine Pyroglutamic acid
Succinic acid
Uric acid
doi:10.1371/journal.pone.0016957.t004
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[70]. These functionalized lipids play important roles in regulating
cell proliferation, apoptosis, tissue repair, blood clotting, blood
vessel permeability, inflammation, pain perception, pancreatic
function, and energy regulation at various levels [71,72,73,74,75].
The oxylipins are classically formed from polyunsaturated fatty
acids through at least three different classes of enzymes: cycloox-
ygenases (COX-1 and COX-2), lipoxygenases (LOX) and cyto-
chrome P450s, or through the direct interaction between unsatu-
rated lipids and reactive oxygen. The reactive oxygen itself may
have either enzymatic (e.g. meyloperoxidase) or non-enzymatic
sources [76]. Among the recognized mammalian oxylipins are the
arachidonic acid-derived prostaglandins, leukotrienes, lipoxins,
hepoxilins, hydroxy, epoxy and dihydroxy metabolites as well as
analogs formed from other highly unsaturated lipids (e.g. resolvins,
protectins), and an array of oxygenated eighteen carbon lipids.
The acyl-ethanolamides and 2-acyl glycerols have emerged as
important endogenous ligands of the cannabinoid receptors, vanilloid
receptors, and peroxisome proliferator activated receptors, and their
regulated synthesis and degradation impacts satiety, thermogenesis,
pain perception, and lipid metabolism [57,77,78] In addition,
circulating levels of acylethanolamides, but not 2-arachidonyl
glycerol, are elevated in cirrhotic liver disease [79] and altered by
psychosocial stress [80]. Interestingly, cross talk between the acyl-
ethanolamine and oxylipin pathways have also been reported [81].
While less well studied, the acyl-glycines represent a growing class of
Table 5. Non-esterified fatty acid concentrations (mM) detected by GC-MS in human plasma.
Compound Name Class HMDB ID Common Abbreviaton
Pennington Plasma
(n=70)
Dodecanoic acid SAT HMDB00638 C12:0 1.4760.68
Myristic acid SAT HMDB00806 C14:0 7.1663
Pentadecanoate SAT HMDB00826 C15:0 1.3460.91
Palmitic acid SAT HMDB00220 C16:0 122648
Heptadecanoic acid SAT HMDB02259 C17:0 1.8960.92
Stearic acid SAT HMDB00827 C18:0 48.8621
Palmitelaidic acid MUFA HMDB12328 C16:1n7t 1.9761.4
Palmitoleic acid MUFA HMDB03229 C16:1n7 9.6666.8
Vaccenic acid MUFA HMDB03231 C18:1n7 10.765
Oleic acid MUFA HMDB00207 C18:1n9 122656
Nonadeca-10(Z)-enoic acid MUFA HMDB13622 C19:1n9 0.64660.37
Eicosenoic acid MUFA HMDB02231 C20:1n9 0.66360.59
Linoleic acid PUFA HMDB00673 C18:2n6 83.8638
Gamma-Linolenic acid PUFA HMDB03073 C18:3n6 1.0861.5
Bovinic acid PUFA HMDB03797 C18:2(9c/t,11t)-CLA 2.0361.3
Alpha- Linolenic acid PUFA HMDB01388 C18:3n3 5.1163.8
Mead acid PUFA HMDB10378 C20:3n9 0.98760.45
Dihomo-gamma-linolenic acid PUFA HMDB02925 C20:3n6 3.6162.1
Arachidonic acid PUFA HMDB01043 C20:4n6 14612
Adrenic acid PUFA HMDB02226 C22:4n6 1.0160.48
-4,7,10,13,16-Docosapentaenoic acid PUFA HMDB13123 C22:5n6 0.95360.51
Stearidonic acid PUFA HMDB06547 C18:4n3 0.40860.4
Timnodonic acid; EPA PUFA HMDB01999 C20:5n3 1.0960.72
Clupanodonic acid; DPA PUFA HMDB06528 C22:5n3 0.99360.46
Cervonic acid; DHA PUFA HMDB02183 C22:6n3 4.6663.3
doi:10.1371/journal.pone.0016957.t005
Table 6. Concentrations of metabolites in healthy serum
performed by GC-MS.
Metabolites Mean (mM) Literature values (mM)
Oxalic acid 22.2 9.262.7
Acetylglycine 69.7 109.4685.6
Myo-inositol 17.1 23.068.0
Uric acid 494.2 302660
Succinic acid 23.5 16.0 (0.0–32.0)
Alpha-Hydroxyisobutyric acid 8.2 7.0 (0.0–9.0)
Ribitol/D-Xylitol ,5 0.46 (0.38–0.55)
Erythronic acid ,5 2.5 (0.0–5.0)
Lauric (Dodecanoic) acid 9.1 12.0 (2.0–37.0)
Phosphoric acid 820.4 1100 (810–1450)
Myristic (Tetradecanoic) acid 9.3 15.464.0
Gluconic acid ,5N A
D-Maltose/L-Arabinose ,5 2.5 (0.0–5.0)
Glyceric acid ,5 2.5 (0.0–5.0)
doi:10.1371/journal.pone.0016957.t006
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of orphan G-protein coupled receptors [82].
Within each of these classes of lipid mediators there exists an array
of isomeric products from of a relatively few fatty acid species making
their separation critical for accurate quantification. Collision induced
dissociation (CID) often yields extensive compound fragmentation
with structurally unique information that aids identification but limits
sensitivity. However, many of these metabolites are present in nM
concentrations, thus detection and quantification tasks are even more
challenging. Over the past two decades GC-MS, LC-MS and LC-
MS/MS methods have all been used to detect, identify and quantify
oxylipins and other polar metabolites, however the latter approach is
associated with simpler sample workup strategies and can simulta-
neously assess a broader range of targets [83]. While knowledge of
normal circulating ranges of some of these mediators may be
valuable, the challenging nature of their detection and quantification
has resulted in limited reporting of their circulating concentrations in
the literature. Given the paucity of such data, we decided to
undertake this targeted study. Not only would the results provide new
and useful information for the serum/blood metabolomics commu-
nity, they would also give a useful assessment of the comparative
strength of targeted LC-MS/MS relative to untargeted methods in
quantitative metabolomics.
Seventy plasma samples collected at the Pennington Research
Center and a triplicate sample (1 sample partitioned into 3
samples) collected by the Human Metabolome Project were
analyzed for subsets of lipid mediators at the USDA-ARS-Western
Human Nutrition Research Center. Surrogate recoveries were
acceptable and are summarized in Table S2. Replicate analysis of
a laboratory reference serum (n=7) analyzed in conjunction with
the Pennington Research Center samples showed excellent
precision, 72% of the oxylipins and 67% of the acyl-glycerol/
amides showed relative standard deviations of ,30% for analytes
with a signal-to-noise ratio .2.
The negative mode UPLC-(2) ESI/MS/MS analysis resulted
in the identification and quantification of 76 oxylipins, including
55 20-carbon polyunsaturated fatty acid-derived oxylipins (Table 7
and Table 8) and 21 18-carbon polyunsaturated fatty-acid-derived
oxylipins (Table 9). The positive mode analysis UPLC-(+)ESI/
MS/MS analysis resulted in the identification and quantification
of 20 acyl-ethanolamides, acyl-glycerols, and acyl-glycines
(Table 10). Collectively, the 2 datasets provide information on
76 oxylipins, 12 acyl-ethanolamide, 6 mono acyl-glycerols, and 2
N-acyl glycines.
While serum and plasma are similar with regards to the
concentration and composition of many small molecules, it is
noteworthy that the physiological concentrations of thromboxanes
in serum and plasma differ greatly. Serum is produced by allowing
whole blood to clot and coagulate, while plasma is the unclotted
liquid fraction of blood. The act of clotting is triggered by platelet
degranulation, which releases thromboxane A2 (TXA2) into the
blood, initiating the clotting response. TXA2 is unstable in aqueous
solution, and is hydrolyzed rapidly into the stable and inactive
thromboxane B2 (TXB2), which reflects TXA2 production and
platelet activation. Therefore, normal plasma TXB2 levels are very
low and range from 0.2 to 2 ng/mL [84]. However, when blood is
allowed to naturally clot, then thromboxane production increases
considerably and its physiological concentration in the resulting
serum has been reported to range from 2 to 178 ng/mL [85].
On the other hand, it is important to mention that non-
esterified fatty acids are well-described circulating components of
human plasma and are influenced by the fed/fasted state, as well
as the metabolic health of the individual. In this regard, it is
noteworthy that the analysis of the plasma sample from the
Human Metabolome Project showed very high long chain n3-
oxylipins, suggesting that this sample was from a person that
consumes high amounts of fish or ingests fish oil supplements. This
is a nice contrast with respect to the Pennington cohort and
indicates the important role that dietary habits play in the oxylipin
composition of blood.
TLC/GC-FID Lipid Analysis
The identification and quantification of a wide array of lipid class
isomers within a single analytical sample (i.e. lipidomics) is a rapidly
Figure 3. Venn diagram showing the overlap of serum metabolites detected by global NMR, GC–MS, LC/GC-FID, LC-ESI-MS/MS and
MS/MS methods compared to the detectable serum metabolome.
doi:10.1371/journal.pone.0016957.g003
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approaches for identifying and/or quantifying lipids. One approach,
known as ‘‘shotgun’’ lipdiomics [88,89], uses LC-MS techniques to
separate lipid classes and mass fragment libraries to identify lipid types.
Shotgun lipidomics is a powerful, non-targeted metabolomic technique
as it allows lipids to be rapidly and ‘‘approximately’’ identified and/or
quantified (if isotopic standards are available). Approximate identifica-
tion means that a lipid might be identified as PC(38:4), meaning that it
is a phosphatidylcholine with two acyl chains that have a total of 4
unsaturated bonds. However, the length of the individual acyl chains,
the sn1/sn2 position of the acyl chains and the position of the
unsaturated bonds is not generally known nor easily knowable. Indeed,
the PC(38:4) designation still means that the lipid could be one of
nearly a dozen possible PC structures.
Table 7. Omega-6 oxylipins (nM) detected by UPLC (2)ESI-MS/MS in human plasma.
Parent Lipid Class
a HMDB ID
Common
Abbreviaton HM Replicate Plasma (n=3) Pennington Plasma (n=70)
C20:4n6 R-OH HMDB05998 20-HETE 1.7760.43 0.91760.58
C20:4n6 R-OH HMDB03876 15-HETE 1.860.098 2.0461.2
C20:4n6 R-OH HMDB04682 11-HETE 0.42560.0095 0.40160.36
C20:4n6 R-OH HMDB06111 12-HETE 6.4260.74 3.9563.3
C20:4n6 R-OH HMDB10222 9-HETE 0.30460.072 0.16660.16
C20:4n6 R-OH HMDB04679 8-HETE 2.0960.16 0.53660.4
C20:4n6 R-OH HMDB11134 5-HETE 0.90160.029 1.0260.79
C20:4n6 R=O HMDB10210 15-KETE 0.74960.08 0.68260.76
C20:4n6 R=O HMDB13633 12-KETE ,0.1 ,0.1
C20:4n6 R=O HMDB10217 5-KETE 0.13660.018 0.14560.12
C20:4n6 R-OOH HMDB04244 15-HPETE NA 1.0660.41
C20:4n6 R-OOH HMDB04243 12-HPETE NA 1.4562.3
C20:4n6 Diol HMDB04385 Lipoxin A4 ,0.07 ,0.07
C20:4n6 Diol HMDB01085 LTB4 0.096860.0062 ,0.1
C20:4n6 Diol HMDB05087 6-trans-LTB4 0.22360.042 ,0.1
C20:4n6 Triol HMDB01509 20-hydroxy-LTB4 NA ,0.1
C20:4n6 Diol HMDB06059 20-carboxy-LTB4 NA ,1
C20:4n6 Diol HMDB10216 5,15-DiHETE 0.24760.02 ,0.07
C20:4n6 Diol HMDB10219 8,15-DiHETE ,0.1 ,0.1
C20:4n6 Diol HMDB02265 14,15-DiHETrE 0.71460.031 0.60360.18
C20:4n6 Diol HMDB02314 11,12-DiHETrE 0.77960.037 0.56660.2
C20:4n6 Diol HMDB02311 8,9-DiHETrE 0.29460.056 0.24460.078
C20:4n6 Diol HMDB02343 5,6-DiHETrE 0.26460.025 0.18960.092
C20:4n6 Epox HMDB04693 14(15)-EpETrE 1.7760.05 0.44260.59
C20:4n6 Epox HMDB10409 11(12)-EpETrE 0.30360.028 1.0261.4
C20:4n6 Epox HMDB02232 8(9)-EpETrE ,0.2 0.62760.71
C20:4n6 Epox HMDB04688 Hepoxilin A3 NA 0.11460.087
C20:4n6 LT HMDB02200 LTE4 NA ,0.6
C20:4n6 TX HMDB03252 TXB2 0.86560.18 0.91961.6
C20:4n6 PG HMDB02886 6-keto-PGF1a 0.35960.023 0.060760.028
C20:4n6 PG HMDB01139 PGF2a 0.3360.018 0.24860.13
C20:4n6 PG HMDB01220 PGE2 0.096760.012 0.17260.13
C20:4n6 PG HMDB01403 PGD2 0.072660.0058 ,0.1
C20:4n6 PG HMDB02710 PGJ2 ,0.3 ,0.3
C20:4n6 PG HMDB04236 PGB2 0.51960.096 ,0.7
C20:4n6 PG HMDB04238 Delta-12-PGJ2 ,0.3 ,0.3
C20:4n6 PG HMDB05079 15-deoxy PGJ2 0.20660.011 ,0.3
C20:4n6 Triol HMDB04684 11,12,15-TriHETrE ,0.1 ,0.1
C20:3n6 R-OH HMDB05045 15-HETrE 0.43760.028 0.73260.45
C20:3n6 PG HMDB01442 PGE1 ,0.1 ,0.1
aClass: R-OH - hydroxy fatty acid; R=O - keto fatty acid; Diol - dihydroxy fatty acid; Triol - trihydroxy fatty acid; Epox - epoxy fatty acid; LT - leukotriene; PG -
prostaglandin.
doi:10.1371/journal.pone.0016957.t007
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lipidomics involves separating lipid classes individually, quantify-
ing the lipid classes, hydrolyzing the lipids into their constituent
acyl chains and then identifying the fatty acids using GC-MS. This
method, which is used by Lipomics Technologies Inc. (now Tethys
Biosciences, Inc.) as well as other, more ‘‘traditional’’ lipid analysis
Table 8. Omega-3 oxylipins (nM) detected by UPLC (2)ESI-MS/MS in human plasma.
Parent Lipid Class
a HMDB ID
Common
Abbreviaton HM Replicate Plasma (n=3) Pennington Plasma (n=70)
C20:5n3 R-OH HMDB10209 15-HEPE 0.2860.042 1.6361.6
C20:5n3 R-OH HMDB10202 12-HEPE 3.1960.35 0.19560.11
C20:5n3 R-OH HMDB05081 5-HEPE 1.1560.14 0.22860.091
C20:5n3 Diol HMDB10211 17,18-DiHETE 14.461.1 2.0860.85
C20:5n3 Diol HMDB10204 14,15-DiHETE ND 0.30460.1
C20:5n3 Epox HMDB10212 17,18-EpETE ND 0.073360.095
C20:5n3 Epox HMDB10205 14,15-EpETE 0.11960.029 ,0.1
C20:5n3 LT HMDB05073 LTB5 0.07960.0056 ,0.1
C20:5n3 PG HMDB02664 PGE3 ND ,0.1
C20:5n3 Triol HMDB10410 Resolvin E1 1.0060.23 0.52160.98
C22:6n3 Epox HMDB13620 19(20)-EpDoPE ND ,0.1
C22:6n3 Epox HMDB13621 16(17)-EpDoPE ND 0.36860.43
C22:6n3 Diol HMDB10214 19,20-DiHDoPE ND 0.80560.42
C22:6n3 R-OH HMDB10213 17-HDoHE ND 0.77360.64
C22:6n3 Triol HMDB03733 Resolvin D1 ND 0.045460.027
aClass: R-OH - hydroxy fatty acid; R=O - keto fatty acid; Diol - dihydroxy fatty acid; Triol - trihydroxy fatty acid; Epox - epoxy fatty acid; LT - leukotriene; PG -
prostaglandin.
doi:10.1371/journal.pone.0016957.t008
Table 9. Octadecanoid oxylipins (nM) detected by UPLC (2)ESI-MS/MS in human plasma.
Parent Lipid Class
a HMDB ID Common Abbreviaton
HM Replicate Plasma
(n=3)
Pennington Plasma
(n=70)
C18:2n6 Diol HMDB04705 12,13-DiHOME 7.6960.59 5.8263
C18:2n6 Diol HMDB04704 9,10-DiHOME 60.563.8 29.7611
C18:2n6 Epox HMDB04702 12(13)-EpOME 4.8860.34 7.2168.8
C18:2n6 Epox HMDB04701 9(10)-EpOME 2.1760.23 5.4767.4
C18:2n6 R-OH HMDB04667 13-HODE 47.360.53 58.2628
C18:2n6 R-OH HMDB10223 9-HODE 11.760.23 1166.1
C18:2n6 R-OOH HMDB03871 13-HpODE ND 6.0165.5
C18:2n6 R-OOH HMDB06940 9-HpODE ND 5.1463.8
C18:2n6 Epox,R=O HMDB13623 12(13)Ep-9-KODE 3.0260.27 3.9662.4
C18:2n6 R=O HMDB04668 13-KODE 4.8260.68 1.761.2
C18:2n6 R=O HMDB04669 9-KODE 2.4160.29 5.362.7
C18:2n6 Triol HMDB04708 9,12,13-TriHOME 0.82760.21 4.1162.2
C18:2n6 Triol HMDB04710 9,10,13-TriHOME 0.51360.083 1.1660.64
C18:3n3 Diol HMDB10208 15,16-DiHODE 14.561 5.9362.4
C18:3n3 Diol HMDB10201 12,13-DiHODE ,0.2 0.21960.12
C18:3n3 Diol HMDB10221 9,10-DiHODE 2.3660.15 0.11460.085
C18:3n3 Epox HMDB10206 15(16)-EpODE 3.2760.23 2.7762.1
C18:3n3 Epox HMDB10200 12(13)-EpODE 0.41660.08 0.46860.67
C18:3n3 Epox HMDB10220 9(10)-EpODE 2.0860.075 1.6562.3
C18:3n3 R-OH HMDB10203 13-HOTE 1.960.21 1.1160.74
C18:3n3 R-OH HMDB10224 9-HOTE 1.9860.12 1.1960.91
Class: R-OH - hydroxy fatty acid; R=O - keto fatty acid; Diol - dihydroxy fatty acid; Triol - trihydroxy fatty acid; Epox - epoxy fatty acid; LT - leukotriene; PG - prostaglandin.
doi:10.1371/journal.pone.0016957.t009
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individual acyl chains to be identified. However, it is not readily
amenable to identifying or quantifying the original or intact lipid.
We chose to use this latter approach, partly because of its
quantitative nature and the fact that combinatorial lipid
reconstruction (CLR) could be used to computationally regenerate
precise lipid structures and to approximate concentration ranges.
The data generated by Lipomics Technologies Inc. for the three
adult serum samples yielded an average number of 26 (ranging
from 23 to 32) unique acyl chains that could be identified and
quantified, comprised of saturated, monounsaturated, polyunsat-
urated (v-3, v-6, v-9, plasmalogen) fatty acids. These acyl chains
were further distributed among 7 distinct lipid classes: 1)
cholesterol esters; 2) diacylglycerols; 3) lysophosphatidylcholines;
4) phosphatidylcholines; 5) phosphatidyl-ethanolamines; 6) free
fatty acids and 7) triacylglycerols. Lipids with more than one fatty
acid chain (phosopholipids, diacyl and triacylglycerols), had their
identities and concentrations determined using combinatorial lipid
reconstruction (CLR, see File S1). CLR uses the fractional
abundance of each fatty acid chain and the total concentration
of a given lipid class to estimate the most probable and upper-limit
concentrations of specific lipids. CLR simplifies to solving a linear
algebra problem with pre-defined constraints thereby allowing one
to estimate most probable and upper limit concentrations. The
most probable concentration corresponds to the concentration a
given lipid is most likely to have, based on the fractional
abundance of all fatty acid components measured for its parent
lipid class. The upper limit concentration corresponds to the
highest possible concentration for a given lipid assuming no other
fatty acid combinations contribute to its total concentration (the
code for lipid quantification is briefly described in File S1).
Using both direct measurements (for CE-esters, free fatty acids
and lysolipids) and CLR (for phospholipids, diacyl and triacylgly-
cerols), we identified and quantified (or semi-quantified) 3,381
lipids. This total included: 25 ‘‘confirmed’’ cholesterol esters, 27
‘‘confirmed’’ free fatty acids, 30 ‘‘confirmed’’ lysophosphatidyl-
cholines (Table 11), 847 ‘‘probable’’ diacylglycerols, 1092
‘‘probable’’ phosphatidylcholines, 1071 ‘‘probable’’ phosphatidyl-
ethanolamines, and 289 ‘‘probable’’ triacylglycerols (the most
abundant ones). The lower limit of quantification of LC/GC-FID
based on the TrueMassH platform and CLR estimates was 9.8 nM
for the diacylglycerol known as (Z,Z)-13,16-docosadienoic acid.
Comparison of the TLC/GC-FID lipid results with literature
data was difficult as relatively few papers report lipid concentration
data for serum and/or plasma. We did find data for a number of
total fatty acids, which showed good agreement with the data
generated by Lipomics Technologies Inc, as seen by comparison
with a cross-sectional study of Kuriki et al [90] in Table S3.
Likewise, total cholesteryl ester concentrations, as opposed to
individual cholesterol esters, also showed generally good agree-
ment with cholesterol measurements reported in the literature
(Table S4). It was also challenging to compare the TLC/GC-FID
lipid results with the GC-MS results as the two methods only
identified and quantified 8 metabolites in common (arachidonic
acid, eicosanoic acid, linoleic acid, oleic acid, palmitelaidic acid,
palmitic acid, stearic acid and tetradecanoic acid). Nevertheless,
the concentration data showed generally good agreement, with
only palmitic acid and oleic acid being substantially different
(TLC/GC-FID concentrations were 50% lower for palmitic acid
and 60% lower for oleic acid). On the other hand, comparison of
the non-esterified or free fatty acids quantitative results between
the TLC/GC-FID and the GC-(+)EI MS platforms shows that the
GC-(+)EI MS concentrations of palmitic acid, vaccinic acid, oleic
acid, linoleic acid, dihomo-c-linolenic acid and docosapenta-
(4,7,10,13,16)-enoic acid are generally higher than those measured
by TLC/GC-FID (Table 6 and Table 11). However, as these were
Table 10. Acyl- ethanolamide, -glycerols, and -glycines concentrations (nM) detected by UPLC (+)ESI-MS/MS in human plasma.
Parent Lipid Class HMDB ID Common Abbreviaton Pennington Plasma (n=70)
C16:0 Ethanolamide HMDB02100 PEA 25.1612
C18:0 Ethanolamide HMDB13078 SEA 15611
C18:1n9 Ethanolamide HMDB02088 OEA 46.8634
C18:2n6 Ethanolamide HMDB12252 LEA 13.766.5
C18:3n3 Ethanolamide HMDB13624 Alpha-LEA 0.11860.069
C20:3n6 Ethanolamide HMDB13625 DGLA EA 1.0160.48
C20:4n6 Ethanolamide HMDB04080 AEA 3.1261.2
C22:4n6 Ethanolamide HMDB13626 DEA 1.6360.78
C22:6n3 Ethanolamide HMDB13627 DHEA 0.40160.22
PGF2a Ethanolamide HMDB13628 PGF2a EA 0.017360.015
PGD2 Ethanolamide HMDB13629 PGD2 EA 0.16160.032
20-HETE Ethanolamide HMDB13630 20-HETE EA 0.020860.013
C18:1n9 1-Acyl Glycerol HMDB11567 1-OG 1706170
C18:2n6 1-Acyl Glycerol HMDB11568 1-LG 37.6636
C20:4n6 1-Acyl Glycerol HMDB11578 1-AG 4.7164.5
C18:1n9 2-Acyl Glycerol HMDB11537 2-OG 1666130
C18:2n6 2-Acyl Glycerol HMDB11538 2-LG 146697
C20:4n6 2-Acyl Glycerol HMDB04666 2-AG 7.864.6
C18:1n9 N-Acyl Glycine HMDB13631 NO-Gly 21623
C20:4n6 N-Acyl Glycine HMDB05096 NA-Gly 1.0960.73
doi:10.1371/journal.pone.0016957.t010
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variation in subjects as opposed to methodological inconsistencies.
A more detailed comparison of the CLR-derived lipid concentra-
tions to those obtained from other MS/MS methods is given
below.
DFI MS/MS
The Direct Flow Infusion (DFI) MS/MS targeted analysis using
the Biocrates AbsoluteIDQ kit provided quantitative results for 139
metabolites (24 acylcarnitines. 14 amino acids, hexose (Table 12),
73 phospatidylcholines (Table S5), 15 sphingomyelins and 12
lysophosphatidylcholines (Table 13). From the 41 measured
acylcarnitines, 24 provided quantitative data, whereas the
remaining 17 were below the limit of detection (LOD). This
result is in good agreement with previous studies conducted by
Biocrates (Application Note 1001-1), which indicated a typical
pool of human plasma from healthy people yields an average of 23
acylcarntines below the limit of detection.
1 That note also reported
that the concentrations of 5 lysophosphatidylcholines in pooled
normal human plasma are typically below the normal LOD,
whereas in the present study only 3 lysophosphatidylcholines were
below the LOD. In our hands, the lower limit of quantification by
DFI MS/MS based on the AbsoluteIDQ kit was 12 nM for
hexadecadienylcarnitine.
The Biocrates DFI MS/MS approach generates lipid data that
is more akin to that measured via shotgun metabolomics (see
above). That is, the lipids are identified by their total acyl/alkyl
chain content (i.e. PC(38:4)) as opposed to their precise chemical
structure. As a result it was difficult to compare lipid concentration
measurements between the Biocrates IDQ platform and the
Lipomics Technology Inc. platform. Nevertheless, by grouping
the diacyl PCs generated by CLR to match the PC designations
Table 11. Concentrations (mM) of cholesterol esters, free fatty acids and lysophospatidylcholines as quantified by TLC/GC-FID.
Cholesterol esters (CEs) Free Fatty Acids (FFAs) Lysopsosphatidylcholines (LysoPCs)
Lipid Class Mean SD Mean SD Mean SD
C14:0 97.04 59.91 15.46 4.02 4.23 1.67
C15:0 ND ND 2.69 0.51 1.76 0.85
C16:0 405.46 56.51 66.01 9.88 106.60 16.73
C18:0 37.50 2.82 41.12 5.52 47.54 8.38
C20:0 1.18 0.12 0.87 0.09 0.69 0.37
C22:0 1.08 0.48 1.01 0.26 0.43 0.09
C24:0 0.91 0.55 0.93 0.19 0.70 0.35
C14:1n5 4.19 1.04 2.02 0.73 0.21 0.08
C16:1n7 118.75 45.54 6.39 4.28 2.34 1.05
C18:1n7 44.23 3.82 2.55 1.31 3.66 0.14
C18:1n9 704.47 129.59 49.24 19.31 37.47 7.73
C20:1n9 0.11 NA 1.50 1.21 0.53 0.17
C20:3n9 2.80 1.49 1.32 1.36 0.25 0.07
C22:1n9 1.86 2.43 1.26 1.59 0.57 0.26
C24:1n9 ND ND 0.90 0.97 0.73 0.56
C18:2n6 1506.38 204.89 14.73 4.33 52.75 6.48
C18:3n6 23.66 1.58 0.31 0.20 0.23 0.10
C20:2n6 4.29 4.02 0.42 0.16 0.71 0.25
C20:3n6 18.71 5.94 0.42 0.21 2.75 0.29
C20:4n6 195.48 21.36 5.26 2.07 8.39 0.98
C22:2n6 1.06 NA 0.42 0.07 0.10 0.11
C22:4n6 ND ND ND ND 0.13 NA
C22:5n6 3.28 3.46 0.14 0.09 0.11 0.02
C18:3n3 23.60 0.13 1.98 1.22 1.24 0.54
C18:4n3 ND ND ND ND 0.29 0.32
C20:4n3 2.47 1.96 0.01 NA 0.26 0.14
C20:5n3 39.07 11.07 0.40 0.07 1.61 0.16
C22:5n3 3.22 3.67 0.39 0.23 0.74 0.22
C22:6n3 21.93 6.64 1.78 0.80 2.78 0.29
dm16:0 ND ND ND ND 0.93 0.11
dm18:0 ND ND ND ND 0.07 NA
dm18:1n9 ND ND ND ND 0.13 NA
doi:10.1371/journal.pone.0016957.t011
1http://www.Biocrates.com/images/stories/pdf/Biocrates_Appl.Note_1001-1.pdf
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correspondence. We found that the concentration data measured
by the Biocrates kit, by Quehenberger et al. [91] and by the
Lipomics platforms matched reasonably well, with the exception of
three cases: 1). PC(28:1), PC(30:2) and PC(38:0) for which CLR
estimated considerably lower most-probable concentrations than
Biocrates; 2). PC(32:0) and PC(36:0) for which CLR estimated
considerably higher; than Biocrates and Quehenberger et al.; and
3) the quantified concentration of PC(40:2) by Quehenberger et al.
[91] which is significantly higher than both Biocrates and CLR
(Table S6). These discrepancies may be due to the fact that
different subjects were analyzed by DFI MS/MS, TLC/GC-FID
and LC-MS/MS. In addition, since CLR takes into account all
possible sn1/sn2 structural combinations, some of these combi-
nations are unavoidably less likely to exist in nature and so these
PCs may be over-represented and therefore generate higher
concentrations. On the other hand, the limits of quantification of
the three platforms are not identical. This means they quantify
different individual fatty acids per lipid class and so they return
different numbers of positional combinations and different PC
concentrations.
Table 12. Concentrations of acylcarnitines and amino acids
(mM) in healthy serum by DFI MS/MS (Biocrates kit).
Acylcarnitines Amino acids
Mean SD Mean SD
DL-carnitine 29.738 7.547 L-Arginine 129.5 30.0
Decanoylcarnitine 0.260 0.111 L-Glutamine 492.6 93.6
Decenoylcarnitine 0.171 0.041 Glycine 329.9 105.6
Decadienylcarnitine 0.061 0.029 L-Histidine 143.1 27.3
Dodecanoylcarnitine 0.103 0.030 L-
Isoleucine+L-
Leucine
227.4 63.5
Tetradecanoylcarnitine 0.043 0.007 L-Methionine 33.4 9.0
Tetradecenoylcarnitine 0.063 0.028 L-Ornithine 93.8 41.3
Tetradecadienylcarnitine 0.028 0.013 L-
Pheylalanine
85.2 23.0
Hexadecanoylcarnitine 0.072 0.019 L-Proline 177.5 38.6
Hexadecenoylcarnitine 0.029 0.005 L-Serine 173.2 51.3
Hexadecadienylcarnitine 0.012 0.002 L-Threonine 102.3 24.6
Octadecanoylcarnitine 0.035 0.010 L-Tryptophan 78.4 15.5
Octadecenoylcarnitine 0.108 0.036 L-Tyrosine 143.0 35.3
Octadecadienylcarnitine 0.035 0.013 L-Valine 266.3 61.0
Acetyl-L-carnitine 5.476 2.147
Propionyl-L-carnitine 0.313 0.154 Hexose
Butyryl-L-carnitine 0.262 0.158 Hexose 3767.6 607.0
Hydroxybutyrylcarnitine 0.106 0.010
Valeryl-L-carnitine 0.142 0.063
Tiglyl-L-carnitine 0.045 0.005
Glutaconyl-L-carnitine 0.018 0.002
Octanoylcarnitine 0.234 0.078
Octenoylcarnitine 0.200 0.151
Nonaylcarnitine 0.033 0.013
doi:10.1371/journal.pone.0016957.t012
Table 14. Comparison of lysophosphatidylcholines
concentrations (mM) performed by LC-ESI-MS/MS and DFI MS/
MS (Biocrates kit).
MS/MS
(Biocrates) LC/GC-FID (Lipomics)
Mean SD Mean SD
LysoPC a C14:0 2.64 0.31 4.23 1.67
LysoPC a C16:0 124.1 50.46 106.6 16.73
LysoPC a C16:1 3.6 1.12 2.34 1.05
LysoPC a C17:0 2.36 1.04 ND ND
LysoPC a C18:0 40.77 20.55 47.54 8.38
LysoPC a C18:1 30.94 10.05 LysoPC C18:1n7 3.66 0.14
LysoPC C18:1n9 37.47 7.73
LysoPC dm18:1n9 0.13 NA
LysoPC a C18:2 32.98 13.31 52.75 6.48
LysoPC a C20:3 2.53 0.74 LysoPC C20:3n6 2.75 0.29
LysoPC C20:3n9 0.25 0.07
LysoPC a C20:4 6.13 2.47 LysoPC C20:4n6 8.39 0.98
LysoPC C20:4n3 0.26 0.14
LysoPC a C24:0 0.19 NA 0.70 0.35
LysoPC a C28:0 0.37 0.06 ND ND
LysoPC a C28:1 0.48 0.1 ND ND
doi:10.1371/journal.pone.0016957.t014
Table 13. Concentrations of sphingomyelins and
lysophosphatidylcholines (mM) in healthy serum by DFI MS/MS
(Biocrates kit).
Sphingomyelins Lysophosphatidylcholines
Mean SD Mean SD
SM (OH)
C14:1
5.92 1.63 LysoPC a C14:0 2.64 0.31
SM (OH)
C16:1
3.70 0.90 LysoPC a C16:0 141 50
SM (OH)
C22:1
15.6 3.7 LysoPC a C16:1 3.48 1.01
SM (OH)
C22:2
12.89 2.88 LysoPC a C17:0 2.55 1.08
SM (OH)
C24:1
2.56 0.66 LysoPC a C18:0 48.5 20.2
SM C16:0 100.5 18.6 LysoPC a C18:1 31.5 10.4
SM C16:1 15.1 3.5 LysoPC a C18:2 30.33 10.3
SM C18:0 25.8 6.4 LysoPC a C20:3 2.65 0.68
SM C18:1 11.7 3.0 LysoPC a C20:4 6.13 2.55
SM C20:2 1.34 0.35 LysoPC a C24:0 0.19 NA
SM C22:3 16.4 7.9 LysoPC a C28:0 0.370 0.043
SM C24:0 30.5 7.6 LysoPC a C28:1 0.481 0.117
SM C24:1 82.7 14.1
SM C26:0 0.440 0.111
SM C26:1 0.850 0.167
a: acyl.
doi:10.1371/journal.pone.0016957.t013
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each other and found that both the Lipomics and Biocrates
platforms provide quite comparable quantification data (Table 14).
Overall, while the compound overlap is relatively small, it appears
that both platforms provide reliable and closely agreeing
measurements of the lipid content in serum.
Method Comparison
We used five different metabolic profiling methods to
experimentally characterize as much of the known serum
metabolome as possible: 1) NMR; 2) GC-MS; 3) lipid mediators
by LC-ESI-MS/MS; 4) lipidomics profiling via TLC/GC-FID-
MS; and 5) DFI MS/MS. We were able to identify a total of 3564
distinct metabolites including several exogenous compounds such
as propylene glycol and acetaminophen. NMR spectroscopy was
able to identify and quantify 49 compounds, GC-MS was able to
identify 90 and quantify 33 compounds, lipid mediator profiling
(targeted ESI-MS/MS) identified and quantified 96 compounds,
TLC/GC-FID-MS identified and quantified 3381 compounds
while DFI MS/MS identified and quantified 139 compounds.
NMR and GC-MS were able to identify a common set of 29
metabolites while NMR, GC-MS and DFI MS/MS were able to
identify a common set of 15 metabolites (14 amino acids and
hexose/glucose). Likewise DFI MS/MS and lipidomics profiling
(TLC/GC-FID-MS) could identify a common set of 53 metabo-
lites. This is summarized in the Venn diagram in Figure 3. These
differences in metabolite coverage arise because of many reasons,
including separation difficulties, sensitivity differences, instrument
detection differences, targeted vs. non-targeted methods, com-
pound stability, compound solubility, compound volatility, etc.
While several pairwise platform comparisons have already been
discussed, it is perhaps instructive to look at how three different
platforms did in the identification and quantification of the one
group of compounds that all three platforms measured: amino
acids. Comparison of amino acid concentrations as measured by
NMR, GC-MS and DFI MS/MS showed that the quantitative
results are in relatively good agreement (Figure 4) A few exceptions
are evident. For example, the NMR concentration of L-alanine is
considerably higher than the GC-MS value. This may be due to
the short GC retention time of L-alanine (,7 min), which overlaps
with non-specified ionized fragments and so an accurate
quantification is impeded. L-Leucine and L-isoleucine cannot be
distinguished with the Biocrates kit and therefore their con-
centrations have been combined from NMR and GC-MS mea-
surements in order to make them comparable with the Biocrates
result.
The considerably higher concentration of L-glutamic acid and
lower concentration of L-glutamine reported by GC-MS relative
to NMR and DFI MS/MS may be due to the hydrolysis of L-
glutamine to L-glutamic acid [92] or the conversion of L-
glutamine to pyroglutamic during derivatization [93]. It has been
reported that the distinction of L-glutamine and pyroglutamic acid
with GC-MS is very difficult, while the identification of L-glutamic
acid and pyroglutamic acid can be complicated [92]. Moreover, it
has been noted that L-cystine can be converted to L-cysteine
during derivatization, while L-cysteine might be oxidized to L-
cystine during prolonged storage of the standard solution [93].
Therefore, L-cystine and L-cysteine determinations have unavoid-
able errors unless they are converted prior to quantification.
Finally, L-arginine and ornithine could not be accurately
Figure 4. Graphical representation of serum concentrations of amino acids by NMR, GC/MS and MS/MS (Biocrates kit). The error bars
reflect 1 standard deviation.
doi:10.1371/journal.pone.0016957.g004
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acid (16.4 min) and secondly because L-arginine is converted to
ornithine during derivatization [94].
While side-by-side platform comparisons for the quantification
of specific metabolites are quite informative, it is also instructive to
compare the different platforms on the basis of their level of
metabolitle coverage. Given that the known, quantifiable serum
metabolome consists of 4229 known and probable metabolites
(665 literature derived metabolites and 3564 experimentally
derived or predicted), we can calculate that NMR is able to
measure ,1.2% (49/4229) of the human serum metabolome, GC-
MS is able to measure 2.13% (90/4229), ESI-MS/MS (lipid
mediator profiling) is able to measure 2.3% (96/4229), TLC/GC-
FID-MS (general lipidomics) is able to measure 79.9% (3381/
4229) while DFI MS/MS is able to measure 3.3% (139/4229) of
the serum metabolome. When combined the five methods are able
to obtain data on 84% of the serum metabolome (3564/4229). It is
important to emphasize that not all of the experimental
approaches used in this study were ‘‘global’’ in their intent,
meaning that the detection and quantification of these metabolites
was not targeted. In particular, the DFI MS/MS and lipid
mediator profiling methods were highly targeted, while the
lipidomics method was generally targeted to lipids and fatty acids.
Likewise, it is also important to emphasize that not all possible
metabolomics platforms or technologies were assessed in this study
nor were some of the latest metabolomics technologies. The use of
more sophisticated or targeted detection and separation protocols
(immunodetection, chemical derivitization, etc.) along with the use
of higher-end instruments (GC-TOF, FT-MS, Orbitraps) would
likely have led to the experimental detection of more compounds.
However for this study, we wanted to address the question of how
well a cross-section of commonly accessible metabolomic methods
or platforms could perform in identifying and quantifying
metabolites in serum.
Given the rich lipid character of serum, lipidomic methods
including lipid mediator profiling, DFI MS/MS and general
lipidomics methods such as TLC/GC-FID-MS appear to be the
most suitable methods for serum characterization – both in terms
of their breadth of coverage and their amenability to quantifica-
tion. In fact, it has been recently postulated that the theoretical
number of distinct lipid isoforms in the human body may
approach 200,000 [95]. Even though the identification and
quantification of such a vast number of lipids is currently not
possible, new advances in MS-based technology are expanding the
number and types of lipids that can be analyzed [95]. Generally
among glycerophospholipids and glycerolipids, the determination
of the length of each fatty acyl moiety at the sn-1 and sn-2
positions of the glycerol backbone and the total number of the
double bonds in each lipid can be unambiguously determined
[95,96,97]. However, the determination of the exact position of
the double bond and the relative number of the positional isomers
poses a major challenge in lipidomics [95,98]. Other challenges
also exist for this field including: 1) the observation that different
classes of lipids may significantly affect instrument response of
[99]; 2) the different patterns that identical lipid species may show
when analyzed by various types of mass spectrometers or by the
same mass spectrometer in different experimental modes [100]
and 3) the limited availability of internal standards with the exact
structure of the lipids of interest [101]. Even with these limitations,
it is still clear that targeted lipid analysis of serum will always yield
an enormous abundance or metabolites.
While NMR and GC-MS do provide information on many
water-soluble metabolites, we believe that these methods are still
insufficiently sensitive to compensate for their lack of coverage.
Overall, it appears that LC-MS or DI-MS methods may be the best
choice for serum metabolomic studies, despite their bias against
hydrophilic metabolites. Interestingly, the use of hydrophobic
enrichment tags (similar in concept to trimethylsilation in GC-
MS)usingp-chlorophenylalaninemediatedchemicallabeling[102],
dimethyl isotopic labeling [103] or dansyl chloride labeling [104]
has been shown to confer enhanced LC retention and improved
MS-detection of hydrophilic metabolites. Preliminary data (Liang
Li, personal communication) suggests this chemo-selective tagging
approach could lead to detection and relative quantification by LC-
FTMS of perhaps 400 water-soluble metabolites in the serum
metabolome.
To summarize, this particular study of the human serum
metabolome was designed to address four key questions: (1) what
compounds can be or have ever been identified in human serum?
(2) What are the concentration ranges for these metabolites? (3)
What portion of the human serum metabolome can be routinely
identified and/or quantified using conventional, untargeted
metabolomics methods? (4) What analytical methods (NMR,
GC–MS, GC-FID, LC–MS) are best suited for comprehensively
characterizing the human serum metabolome? The answers to the
first two questions have already been given and the information is
contained in the human serum metabolome database (SMDB –
http://www.serummetabolome.ca). With respect to the third
question, given that the known, quantifiable serum metabolome
consists of 4229 confirmed and probable metabolites, we observe
that NMR is able to measure ,1.2% (49/4229) of the human
serum metabolome, GC-MS is able to measure 2.13% (90/4229),
ESI-MS/MS (lipid mediator profiling) is able to measure 2.3%
(96/4229), TLC/GC-FID-MS (general lipidomics) is able to
measure the concentration of 79.9% (3381/4229) while DFI
MS/MS is able to access 3.3% (139/4229) of the serum
metabolome. When combined the five methods are able to obtain
data on 84% of the serum metabolome (3564/4229).
While clear differences do exist in the number and type of
compounds detected by the technologies employed in this study, the
intent was not to denigrate any technology, but simply to explore
their limits (strengths and weaknesses) and to characterize the
human serum metabolome with a cross-section of commonly
available metabolomics tools or platforms. Indeed, this study
suggests that comprehensive metabolite profiling of human serum
requires multiple platforms and multiple methods as no single
method can offer (nor likely will offer) complete metabolite
coverage. Despite these caveats, it is fairly clear that non-targeted
lipidomics (TLC/LC-GC-FID) using combinatorial lipid recon-
structionappearstobethebest method forgetting thelargestdegree
of metabolite coverage, even though many of the metabolites and
concentrations generated through the CLR method would have to
be called ‘‘probable’’ rather than confirmed. However, this
approach is time-consuming, expensive, requires relatively large
sample volumes and is focused on the lipid classes specifically, thus
providing limited coverage of metabolic space. The use of targeted
metabolite profiling approaches (such as lipid mediator profiling or
the DI MS/MS kit), while not as comprehensive, shows good
promise and exceptional sensitivity. Furthermore, both methods
allow specific expansion into other regions of metabolic space. In
particular, the low volume requirements (10–20 mL) and the high-
throughput nature (80 samples/day) of kit-based technologies such
as the Biocrates AbsoluteIDQ kit could make this approach
particularly appealing to many labs. While NMR may be the most
robust technology for quantitative metabolomics, the high volume
requirements (.300 mL) and general lack of sensitivity (.1 mM)
tend to make this approach somewhat limiting. The reduced
sensitivity obviously means NMR-based approaches will tend to
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oxidation-status markers) of clinical interest. Overall, GC–MS
appears to have similar or slightly better sensitivity than NMR
spectroscopy, although quantification by GC-MS tends to be more
difficult. It is notable that GC-MS volume requirements are often
substantially less than NMR, making GC-MS a more powerful
approach to doing metabolomics with volume-limited samples.
Potentially, the use of GC–TOF instrument or a fast scanning
quadrupole instrument would have yielded even more favorable
results for our GC–MS studies.
Obviously, if time and resources permitted, we would have liked
to assess other technologies and to study a much broader patient
base. However, this study is not the ‘‘final’’ word on serum or
blood metabolomics. Rather, it should be viewed as a starting
point for future studies and future improvements in this field.
Indeed, our primary objective for undertaking these studies and
compiling this data was to help advance the fields of quantitative
metabolomics, especially with regard to clinically important
biofluids. Experimentally, our data should serve as a useful
benchmark from which to compare other technologies and to
assess coming methodological improvements in human serum
characterization. From a clinical standpoint, we think the
information contained in the human serum metabolome database
(SMDB) should provide clinicians and clinical chemists a
convenient, centralized resource from which to learn more about
human serum and its unique biochemical functions.
Methods
Ethics Statement
All samples were collected in accordance with the ethical
guidelines and written consent protocols mandated by the
University of Alberta, the University of British Columbia (UBC)
and the Pennington Biomedical Research Centre (PBRC). All
three institutional review boards approved the collection of serum
for comprehensive metabolite characterization. All patients and all
control individuals were approached using approved ethical
guidelines and those who agreed to participate in this study, were
required to sign consent forms. Patients could refuse entry,
discontinue participation, or withdraw from the study at any time
without prejudice to further treatment or management. All
participants provided written consent.
Sample Collection and Preparation
Four different sets of blood or serum samples were collected for
our experimental studies (Table 1). A set of 54 adult serum samples
was collected specifically for quantitative NMR, untargeted GC-
MS and targeted (DFI) MS/MS studies, and a second set of 3
samples was collected and analyzed using quantitative lipidomics
assays (TLC-methyl-esterification-GC-MS) developed by Lipomics
Technologies Inc. (now Tethys Inc., West Sacramento, CA). The
small number of samples used for the lipidomic assays were
dictated by the substantial time and cost associated with these
targeted quantitative studies. A third set of plasma samples was
collected from 70 healthy subjects for the determination of
nonesterified lipids and lipid mediators, including oxylipins and
endocannabionids, by targeted GC-MS and UPLC-MS/MS. A
fourth set comprised of 3 technical replicates of one adult serum
sample, was collected and analyzed for oxylipins by UPLC-ESI-
MS/MS in an independent analysis.
For the untargeted NMR and GC-MS studies, we also explored
temporal and disease-associated metabolite differences to get a
better idea of the extent of the cross-sectional and longitudinal
metabolite variability for NMR-detectable blood metabolites.
Because of the close clinical monitoring and frequent blood
sampling done of organ transplant patients, we chose to work with
a small cohort of heart transplant patients enrolled as part of the
Biomarkers in Transplantation study at the James Hogg iCAP-
TURE Centre at St. Paul’s Hospital in Vancouver BC. As a result,
for the NMR, GC-MS and MS-MS studies, serum samples were
collected from 21 healthy adult individuals (aged 26–71) (mentioned
above) and 9 heart transplant patients (aged 26–64). Six serum
samples were collected for each of the heart transplant patients at
various time points (before transplantation, then 2, 3, 4, 8, and 12
weeks after transplantation) for a total of 966=54 samples. The
heart transplant patients included 6 males and 3 females.
Blood samples obtained from the transplant patients (54
samples) or controls (21 for NMR, GC-MS, MS-MS, 1 for LC/
MS, 3 for GC-MS/lipidomics) were collected via standard
overnight fasting, vein-puncture methods and stored in serum
tubes (with clot promoter). Samples were subsequently spun down
for 15 minutes at 29006ga t4 uC and the serum decanted into
clean plastic cryogenic vials and frozen to 280uC within 2 hours
to minimize any possible metabolite degradation. All serum
samples were thawed on ice for approximately 2 hours before use.
For the targeted analysis of nonesterified fatty acids, oxylipins,
acylamides, and monoacylglycerols in plasma, compiled results
were obtained from a study designed to assess the roles of lipids
and hormones in regulating blood pressure in subjects with
varying amounts of body fat. Subjects were healthy adults, ages 35
to 65 (32 males and 37 females) with each gender group
comprising approximately half African Americans and half
Caucasians. The subject groups displayed a representative range
of body habitus with a BMI of 2965 kg/m
2. The study took place
in a clinical research unit at the Pennington Biomedical Research
Center in Baton Rouge, LA. A standard diet was given to subjects
to eat for four days, three days while they lived at home, and the
fourth day in the clinical research unit. Blood samples were drawn
in the morning after an overnight fast and before subjects arose
from bed. Venous blood was drawn into a tube containing EDTA,
immediately chilled on ice for transport, centrifuged within an
hour, and the plasma decanted into storage tubes. Storage was at
280uC for several months before analysis.
NMR Compound Identification and Quantification
Serum samples contain a substantial portion of large molecular
weight proteins and lipoproteins, which affects the identification
and quantification of small molecule metabolites by NMR
spectroscopy. Consequently, we introduced a step in the protocol
to remove serum proteins (deproteinization). There are several
routes to serum deproteinization, including organic solvent
(acetonitrile, methanol, isopropanol) precipitation, ultrafiltration
[28,44] as well as spectral manipulation methods such as diffusion
editing [45]. While other researchers have found that ultrafiltra-
tion yields poor signal-to-noise ratios, we found that by using an
ultrafiltration protocol similar to that described by Tiziani [46]
and Weljie et al [47], we could obtain excellent spectra that
yielded metabolite concentrations that closely matched known
values measured using standard clinical chemistry techniques.
Ultrafiltration also has other advantages: it is relatively quick,
very reproducible, does not introduce unwanted solvent peaks
and is ‘‘safe’’ in terms of avoiding unwanted side-reactions with
biofluid metabolites. All
1H-NMR spectra were collected on a
either a 500 MHz or 800 MHz Inova (Varian Inc., Palo Alto,
CA) spectrometer using the first transient of the tnnoesy-
presaturation pulse sequence. The resulting
1H-NMR spectra
were processed and analyzed using the Chenomx NMR Suite
Professional software package version 6.0 (Chenomx Inc.,
The Human Serum Metabolome
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the NMR sample preparation and NMR data acquisition are
provided in File S1.
GC-MS Compound Identification and Quantification
Seven of the 21 normal serum samples were chosen for GC-MS
analysis and aliquots from these provided an additional ‘‘pooled
normal’’ sample (the heart transplant serum samples were not
analyzed). All samples were extracted separately to obtain separate
pools of polar and lipophilic metabolites using different protocols.
The polar extraction protocol was adapted from a previously
reported method [42] used to deproteinize and solubilize polar
metabolites. Lipophilic metabolites were obtained by extracting
serum samples using a mixture of cold HPLC grade chloroform/
methanol as previously described [48]. All samples were
derivatized with MSTFA (N-Methyl-N-trifluoroacetamide) with
1% TMCS (trimethylchlorosilane) and the resulting extracts were
separated and analyzed using an Agilent 5890 Series II GC-MS
operating in electron impact (EI) ionization mode. Further details
on the extraction, derivatization, separation and GC-MS data
analysis are provided in File S1.
Targeted Profiling of Lipids and Lipid Mediators
Low to moderate abundance lipids and lipid-derived mediators
in blood plasma were quantified using targeted GC-MS and LC-
MS/MS analyses. Non-esterified fatty acids were methylated and
quantified using modifications of the extractive methylation
procedure of Pace-Asiack [49]. The GC-MS analyses were
performed on an Agilent 6890 GC 5973N MSD with a
30 m60.25 mm id60.25 mm DB-225ms column using splitless
injections (see File S1 for further details).
Oxylipins [50,51,52,53,54,55] acylethanolamides [56,57,58],
monoacylglycerols [59], and N-acylglycines [60,61,62] are impor-
tant classes of low to moderate abundance blood-borne lipophilic
molecules with recognized regulatory functions in inflammation,
blood pressure, satiety, gut motility, energy balance, and pain
regulation [54,55]. While the importance of circulating levels of
some of these metabolites is debated, given their clinical
importance, we believed that establishing their normal ranges in
the circulating blood metabolome would be valuable. However, as
a host of these agents are either involved in or affected by the
clotting process, their values were determined in plasma (not
serum) from blood collected in the presence of potassium EDTA.
These benchmark values were established in an independent
cohort of age (4967 yr) and BMI (2965 kg/m
2) matched African
American and Caucasian men and women (n=70). The plasma
samples were extracted by solid phase extraction (SPE) and
analyzed by UPLC-MS/MS for non-esterified oxylipins, acyletha-
nolamides, N-acylglycines, and monoacylglycerols using modifi-
cations of previously described protocols [63]. Analytes were
separated using an Acquity UPLC (Waters Corp), followed by
MS/MS analysis on an ABI 4000 Q-Trap (Applied Biosystems).
Oxylipins were detected using negative mode electrospray
ionization, while all other residues were detected in positive mode.
Compounds were quantified with six point calibration curves using
a ratio response to stable isotope surrogates, using the Analyst
software package (Applied Biosystems). Additional details on the
extraction, calibration and processing are available in File S1.
TLC/GC-FID Lipid Identification and Quantification
Serum and plasma are particularly rich in lipids and lipoprotein
particles. To identify and quantify common lipids in serum a total
of three human serum samples were analyzed using the
TrueMassH platform developed by Lipomics Technologies Inc.
(West Sacramento,CA; now Tethys Bioscience, Inc.). This method
can be used to identify and quantify distinct lipid classes including
neutral lipids, such as cholesterol esters (CEs), free fatty acids
(FFAs), triacylglycerols (TGs) and diacylglycerols (DGs) as well as
phospholipids such as lysophosphatidylcholines (LysoPCs), phos-
phatidylcholines (PCs) and phosphatidyl-ethanolamines (PEs). The
methods used by Lipomics Technologies Inc. are described in
more detail in a number of patents (US Patent #10753289, WO/
2003/005628, see also reference [64] and File S1).
The major fatty acid constituents detected by this technique
include all C12 to C24 saturated and unsaturated chains (.25
fatty acids in total). Quantification of the lipids and fatty acids was
achieved using defined fatty acid methyl ester standards. A
computational method called Combinatorial Lipid Reconstruction
(CLR) was used to ‘‘regenerate’’ the structures and estimate the
most probable concentrations of the triacylglycerols, diacylglycer-
ols and phospholipids with .1 fatty acid chain. CLR uses the
fractional abundance of each fatty acid chain and the total
abundance of a given lipid class to estimate most probable and
upper limit concentrations of a given lipid (see File S1 for a
detailed description of CLR).
Direct Flow Injection MS/MS Compound Identification
and Quantification
To assess the performance of direct flow injection (DFI) MS/
MS methods in serum metabolomics and to determine the
concentration ranges of a number of metabolites not measurable
by other methods, we used the commercially available Absolute-
IDQ kit (Biocrates Life Sciences AG - Austria). This kit, in
combination with an ABI 4000 Q-Trap (Applied Biosystems/
MDS Sciex) mass spectrometer, can be used for the targeted
identification and quantification of 160 different metabolites
including amino acids, acylcarnitines, glycerophospholipids, and
sphingolipids. The method involves derivatization and extraction
of analytes from the biofluid of interest, along with selective mass-
spectrometric detection and quantification via multiple reaction
monitoring (MRM). Isotope-labeled internal standards are inte-
grated into the kit plate filter to facilitate metabolite quantification
(see File S1 for additional information).
Literature Survey of Human Serum Metabolites
In addition to these experimental studies, a complete literature
review of known metabolites and metabolite concentrations in
human serum and plasma was also conducted. A number of
standard clinical chemistry textbooks [22,27,65,66] provided
reference values and disease concentrations for approximately
100 commonly measured blood metabolites. To supplement these
data, we employed several computational text-mining tools that
were originally developed for the Human Metabolome Database
and subsequently used in the determination of the human
cerebrospinal fluid metabolome [15]. One of the more useful
programs was the in-house text mining tool called PolySearch [67]
(http://wishart.biology.ualberta.ca/polysearch/). This program
was used to generate a hyperlinked list of abstracts and papers
from PubMed containing relevant information about serum
metabolites and their concentration data. Specifically, PolySearch
compiled a ranked list of metabolites based on the frequency of
word co-occurrence with the terms ‘‘serum’’, ‘‘plasma’’ or ‘‘blood’’
in conjunction with words such as ‘‘concentration’’, ‘‘identifica-
tion’’, ‘‘quantification’’, ‘‘mM’’, ‘‘nM’’ or ‘‘micromol’’. The list of
metabolites and metabolite synonyms was compiled from the
HMDB [4,5], KEGG [6], ChEBI [9] and PubChem [68].
PolySearch also extracted key sentences from the abstracts, then
labeled and hyperlinked the metabolites mentioned in the text.
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than 2000 ‘‘highly informative’’ papers or abstracts. From these
abstracts and papers, our annotators manually extracted metab-
olite information (metabolite identities, concentrations, disease
states, etc.) and entered the data into our laboratory information
management system (LIMS) called MetboLIMS. The resulting list
of literature-derived metabolites helped confirm the identity of
many metabolites found in our experimental analyses. The
literature-derived concentration values also simplified some of
the searches for putative metabolite matches in our experimental
studies (described above). In total we identified 665 metabolites
and obtained nearly 1000 metabolite concentration values using
these bibliomic or text mining approaches.
Metabolite Validation and Verification
Ac o m m o nw e a k n e s st om a n ym e t a b o l o m i cs t u d i e si st h e
presumption that all named metabolites are equally valid and fully
verified. This is often not the case. For instance if a metabolite has been
identified only through a parent ion mass match to a database
compound, its identity should only be considered very tentative. On
the other hand if a compound has been identified through an exact
match to all 24 of its characteristic NMR peaks, or through matching
the retention time, parent ion mass and mass fragment patterns of a
known standard then obviously this compound’s identity is on much
more solid ground. In a study as broad and complex as this one, it is
important to understand that some metabolites have only been
tentatively identified while others have been fully confirmed or
validated. Among the experimentally identified compounds reported
here, authentic standards, exact NMR spectral matches or spike-in
e x p e r i m e n t sw e r eu s e dt oc o n f i r mt h ei d e n t i t yo fa l m o s ta l lt h e
c o m p o u n d si no u rN M R ,D F IM S / M S ,o x y l i p i na n dl i p i d o m i c s
studies (see File S1 for additional details). Therefore most of these
compounds should be considered as ‘‘confirmed’’. For the CLR
assembled lipids, all the component parts (head groups and acyl chains)
werepositivelyidentifiedand verified usingauthentic standards, butthe
intact lipid could not be verified. Consequently the triacylglycerols,
diacylglycerols and phospholipids reported here should be considered
as ‘‘probable’’. For the GC-MS studies some compound spiking was
performed, but not every compound was validated with authentic
standards. As a rule if a compound had an AMDIS match factor of
.60% and a probability score .20% as well as a matching retention
index to a known compound it was considered ‘‘probable’’. If that
compound had been previously identified by another method and if
the concentration matched closely with a previously reported value, it
was considered ‘‘confirmed’’. With regard to the veracity of
compounds compiled from the literature, obviously a different set of
rules is required. For those compounds cited and quantified by
standard clinical textbooks as well as those identified by two or more
independent published studies were considered ‘‘confirmed’’. Those
compounds with only a single literature reference were considered as
‘‘probable’’ unless the presented evidence was overwhelming. These
verification labels have been added to all the compound data in the
Serum Metabolome Database (see below).
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